Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 19, 2023 - Issue 3
Submit an article Journal homepage
1,044
Views
0
CrossRef citations to date
0
Altmetric
HPV

Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018–2020

Qianhui Wua Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai, ChinaView further author information
,
Mengcen Qiana Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai, China;b Key Laboratory of Health Technology Assessment, Ministry of Health, Fudan University, Shanghai, ChinaView further author information
,
Sarah Welbyc GSK, Wavre, BelgiumView further author information
,
Adrienne Guignardc GSK, Wavre, BelgiumView further author information
,
Dominique Rosillonc GSK, Wavre, BelgiumView further author information
,
Kusuma Gopalad GSK, Bangalore, IndiaView further author information
,
Yuan Xue GSK, Wuhan, ChinaView further author information
,
Keruo Liuf GSK, Shanghai, ChinaView further author information
,
Yunkun Hef GSK, Shanghai, ChinaView further author information
,
Ning Jiangf GSK, Shanghai, ChinaView further author information
,
Qin Tang Shunde District Center for Disease Control and Prevention, Guangdong, ChinaView further author information
,
Jiamin Xieg Shunde District Center for Disease Control and Prevention, Guangdong, ChinaView further author information
,
Taoying Zhuh Wuhou District Center for Disease Control and Prevention, Sichuan, ChinaView further author information
,
Qizhang Wangi Pudong New Area Center for Disease Control and Prevention, Shanghai, ChinaView further author information
,
Yingzi Panj Wujin District Center for Disease Control and Prevention, Jiangsu, ChinaView further author information
,
Ruikun Zengk Longgang District Center for Disease Control and Prevention, Guangdong, ChinaView further author information
,
Jie Yangl Luohu District Center for Disease Control and Prevention, Guangdong, ChinaView further author information
,
Xiaoqian Zhaom Taocheng District Center for Disease Control and Prevention, Hebei, ChinaView further author information
,
Man Zhoun Xicheng District Center for Disease Control and Prevention, Beijing, ChinaView further author information
,
Adoración Navarro-Tornéc GSK, Wavre, BelgiumView further author information
,
Hongjie Yua Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai, China;o Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China;p Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6335-5648View further author information
ORCID Icon &
Dorota Borysc GSK, Wavre, BelgiumView further author information
 show all
Article: 2283912 | Received 27 Jun 2023, Accepted 11 Nov 2023, Published online: 01 Dec 2023

References

  • Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. Human papillomavirus and related diseases in the world. ICO/IARC information centre on HPV and cancer (HPV Information Centre). 2021 [accessed 2022 Mar 15]. https://hpvcentre.net/statistics/reports/XWX.pdf.
  • de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–10. doi:10.1016/S2214-109X(19)30488-7.
  • de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56. doi:10.1016/S1470-2045(10)70230-8.
  • Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19. doi:10.1002/(SICI)1096-9896(199909)189:1<12:AID-PATH431>3.0.CO;2-F.
  • World Health Organization. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009;84(15):118–31. https://pubmed.ncbi.nlm.nih.gov/19360985/.
  • Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gomez D, Munoz J, Bosch FX, de Sanjose S. 2023 Human papillomavirus and related diseases in China. Summary report 10 March 2023. ICO/IARC information centre On HPV and cancer (HPV Information Centre). [ accessed 2023 Sep 14]. https://hpvcentre.net/statistics/reports/CHN.pdf.
  • Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32. doi:10.3322/caac.21338.
  • Bao HL, Jin C, Wang S, Song Y, Xu ZY, Yan XJ, Li LM, Ning Y, Wang HJ. Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: a nationwide population-based study. J Infect. 2021;82:75–83. doi:10.1016/j.jinf.2021.02.017.
  • Li H, Li P, Huang L, Sun L, Ren H, Li P. Prevalence characteristics of cervical human papillomavirus (HPV) infection in the Zhoupu district, Shanghai city, China. Virol J. 2020;17:84. doi:10.1186/s12985-020-01352-8.
  • Luo LP, He P, Liu QT, Jiang YH, Zhang YN, Li QZ, Li Q, Li ST, Yang F, Ling H, et al. Prevalence and genotype distribution of HPV infection among 214,715 women from southern China, 2012-2018: baseline measures prior to mass HPV vaccination. BMC Infect Dis. 2021;21:328. doi:10.1186/s12879-021-06019-5.
  • Yan X, Huang Y, Zhang M, Hu X, Li K, Jing M. Prevalence of human papillomavirus infection and type distribution among Uyghur females in Xinjiang, northwest China. Oncol Lett. 2020;20:25. doi:10.3892/ol.2020.11886.
  • Zhu X, Wang Y, Lv Z, Su J. Prevalence and genotype distribution of high-risk HPV infection among women in Beijing, China. J Med Virol. 2021;93:5103–9. doi:10.1002/jmv.27013.
  • Pan XF, Li R, Pan A, Larson H. Human papillomavirus vaccine approval in China: a major step forward but challenges ahead. Lancet Infect Dis. 2016;16:1322–3. doi:10.1016/S1473-3099(16)30450-9.
  • Wong LP, Han L, Li H, Zhao J, Zhao Q, Zimet GD. Current issues facing the introduction of human papillomavirus vaccine in China and future prospects. Hum Vaccin Immunother. 2019;15:1533–40. doi:10.1080/21645515.2019.1611157.
  • GSK. Cervarix Summary Of Product Characteristics. Rixensart, Belgium: GSK; 2020 [accessed 2021 May 10]. https://www.ema.europa.eu/en/documents/product-information/cervarix-epar-product-information_en.pdf.
  • Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398:2084–92. doi:10.1016/S0140-6736(21)02178-4.
  • Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, Cruickshank M. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. 2019;365:l1161. doi:10.1136/bmj.l1161.
  • Porras C, Tsang SH, Herrero R, Guillén D, Darragh TM, Stoler MH, Hildesheim A, Wagner S, Boland J, Lowy DR, et al. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica vaccine trial. Lancet Oncol. 2020;21:1643–52. doi:10.1016/S1470-2045(20)30524-6.
  • Zhu FC, Chen W, Hu YM, Hong Y, Li J, Zhang X, Zhang YJ, Pan QJ, Zhao FH, Yu JX, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Int J Cancer. 2014;135:2612–22. doi:10.1002/ijc.28897.
  • CIOMS Working Group VI. Management of safety information from clinical trials. Report of CIOMS working group VI. Council for international organizations of medical Sciences (CIOMS). Geneva, CH; 2005 [accessed 2021 May 5]. https://cioms.ch/wp-content/uploads/2017/01/Mgment_Safety_Info.pdf.
  • Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, Pan QJ, Zhang WH, Zhao FH, Zhang CF, et al. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: end-of-study results from a phase II/III, randomised, controlled trial. Cancer Med. 2019;8:6195–211. doi:10.1002/cam4.2399.
  • Gonçalves AK, Cobucci RN, Rodrigues HM, de Melo AG, Giraldo PC. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review. Braz J Infect Dis. 2014;18:651–9. doi:10.1016/j.bjid.2014.02.005.
  • Willame C, Rosillon D, Zima J, Angelo MG, Stuurman AL, Vroling H, Boggon R, Bunge EM, Pladevall-Vila M, Baril L. Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Hum Vaccin Immunother. 2016;12:2862–71. doi:10.1080/21645515.2016.1199308.
  • ANSM. Vaccins anti-HPV et risque de maladies auto-immunes: étude pharmacoépidémiologique. Paris, France; 2015 [accessed 2021 May 10]. https://www.snds.gouv.fr/download/Epidemio/rapport_final_ANSM_Cnamts_vaccins_anti_hpv_Septembre_2015.pdf.
  • Collin C, Miranda S, Zureik M, Dray-Spira R. HPV vaccines and the risk of thyroiditis in girls. Complementary analyses of the French cohort based on data from SNIIRAM. France: ANSM, Saint Denis; 2017.
  • Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: a self-controlled case-series study in England. Vaccine. 2017;35:1729–32. doi:10.1016/j.vaccine.2017.01.076.
  • Lehtinen M, Eriksson T, Apter D, Hokkanen M, Natunen K, Paavonen J, Pukkala E, Angelo MG, Zima J, David MP, et al. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: interim analysis of a large community-randomized controlled trial. Hum Vaccin Immunother. 2016;12:3177–85. doi:10.1080/21645515.2016.1183847.
  • Rosillon D, Willame C, Tavares Da Silva F, Guignard A, Caterina S, Welby S, Struyf F. Meta-analysis of the risk of autoimmune thyroiditis, guillain-barré syndrome, and inflammatory bowel disease following vaccination with AS04-adjuvanted human papillomavirus 16/18 vaccine. Pharmacoepidemiol Drug Saf. 2020;29:1159–67. doi:10.1002/pds.5063.
  • Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, Pan QJ, Zhang WH, Zhao FH, Zhang CF, et al. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial. Cancer Med. 2017;6:12–25. doi:10.1002/cam4.869.
  • Baril L, Rosillon D, Willame C, Angelo MG, Zima J, van den Bosch JH, Van Staa T, Boggon R, Bunge EM, Hernandez-Diaz S, et al. Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Vaccine. 2015;33:6884–91. doi:10.1016/j.vaccine.2015.07.024.
  • López-Fauqued M, Zima J, Angelo MG, Stegmann JU. Results on exposure during pregnancy from a pregnancy registry for AS04-HPV-16/18 vaccine. Vaccine. 2017;35:5325–30. doi:10.1016/j.vaccine.2017.08.042.
  • Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89–99. doi:10.1016/S1470-2045(11)70286-8.
  • Dai L, Zhu J, Liang J, Wang YP, Wang H, Mao M. Birth defects surveillance in China. World J Pediatr. 2011;7:302–10. doi:10.1007/s12519-011-0326-0.
  • Lobo I, Zhaurova K. Birth defects: causes and statistics. Nat Educ. 2008;1:18. www.nature.com/scitable/topicpage/birth-defects-causes-and-statistics-863.
  • WHO. Questions and answers about human papillomavirus (HPV). Copenhagen, Denmark: World Health Organization Regional Office for Europe; 2020 [accessed 2021 May 14]. https://www.euro.who.int/__data/assets/pdf_file/0003/427017/WHO-HPV-QA.pdf.
  • Tavares Da Silva F, De Keyser F, Lambert PH, Robinson WH, Westhovens R, Sindic C. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine. 2013;31:1870–6. doi:10.1016/j.vaccine.2013.01.042.
  • Yang Y, Zhou X, Gao S, Lin H, Xie Y, Feng Y, Huang K, Zhan S. Evaluation of electronic healthcare databases for post-marketing drug safety surveillance and pharmacoepidemiology in China. Drug Saf. 2018;41:125–37. doi:10.1007/s40264-017-0589-z.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.